LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

12.64 0.4

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.16

Máximo

12.76

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.989 49.8
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+55.4% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.3B
Apertura anterior	12.24
Cierre anterior	12.64

Noticias sobre sentimiento de mercado

By Acuity

50%

175 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 may 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 may 2026, 23:46 UTC

Charlas de Mercado

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 may 2026, 23:33 UTC

Charlas de Mercado

Gold Rises on Possible Position Adjustments -- Market Talk

11 may 2026, 22:37 UTC

Charlas de Mercado

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 may 2026, 22:32 UTC

Ganancias

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 may 2026, 22:02 UTC

Charlas de Mercado

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 may 2026, 21:49 UTC

Ganancias

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 may 2026, 21:42 UTC

Charlas de Mercado

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 may 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 may 2026, 21:23 UTC

Adquisiciones, fusiones, absorciones

CSG Systems Sale to NEC Gets CFIUS Clearance

11 may 2026, 21:12 UTC

Ganancias

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 may 2026, 21:12 UTC

Ganancias

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

11 may 2026, 20:44 UTC

Ganancias

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 may 2026, 20:43 UTC

Ganancias

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 may 2026, 20:32 UTC

Ganancias

CleanSpark 2Q Rev $136.4M >CLSK

11 may 2026, 20:30 UTC

Ganancias

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Cont Ops EPS $2.24 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Rev $1.6B >STE

11 may 2026, 20:30 UTC

Ganancias

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 may 2026, 20:30 UTC

Ganancias

Steris 4Q Adj EPS $2.83 >STE

11 may 2026, 20:22 UTC

Acciones populares

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 may 2026, 19:37 UTC

Ganancias

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 may 2026, 19:32 UTC

Charlas de Mercado

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

55.4% repunte

Estimación a 12 Meses

Media 20 USD 55.4%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

175 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.